23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
20:15 , Mar 24, 2017 |  BC Week In Review  |  Financial News

Heat Biologics completes follow-on

On March 23, immuno-oncology company Heat Biologics Inc. (NASDAQ:HTBX) raised $4 million through the sale of 5 million shares at $0.80 in a follow-on underwritten by Aegis Capital. Heat Biologics Inc. (NASDAQ:HTBX) Durham, N.C. ...
21:55 , Jan 20, 2017 |  BC Week In Review  |  Company News

Heat, Shattuck deal

Heat granted newco Shattuck an exclusive license to Heat technology, which Shattuck will use to develop its agonist redirected checkpoint (ARC) platform technology. The technology blocks checkpoint molecules and stimulates tumor necrosis factor (TNF) superfamily...
21:37 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

HS-410: Additional Ph I/II data

Data from 94 patients with intermediate- or high-risk non-muscle invasive bladder cancer who have undergone transurethral resection of bladder tumor in the Phase II portion of a double-blind, U.S. Phase I/II trial showed that both...
01:48 , Dec 22, 2016 |  BC Innovations  |  Product R&D

Fever pace for Zika

In less than two years since emerging as a global threat, the Zika virus has prompted an unprecedented acceleration of public and private translational research that has already put three vaccine candidates in the clinic....
00:57 , Nov 8, 2016 |  BC Extra  |  Clinical News

Antibody protects fetuses from Zika in preclinical model

Researchers showed that an antibody reduced viral load in pregnant mice infected with Zika virus, suggesting it could protect fetuses from Zika infection. In a paper published Monday in Nature , a team led by...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

Heat Biologics, University of Miami deal

Heat Biologics and the university partnered to develop vaccines to treat Zika, HIV, West Nile, dengue and yellow fever virus infections based on Heat’s heat shock 90 kDa protein beta 1 ( Hsp90B1 ; GP96...
07:00 , Oct 25, 2016 |  BC Extra  |  Clinical News

Heat, UMiami seek to create fetal Zika vaccine

Heat Biologics Inc. (NASDAQ:HTBX) and the University of Miami said they are collaborating to develop vaccines targeting the Zika virus and other infectious diseases based on Heat's heat shock 90 kDa protein beta 1 (...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Company News

Heat Biologics, Adaptive Biotechnologies deal

Heat and Adaptive partnered to discover immune biomarkers for Heat’s immunotherapies, including HS-410 . The partners will use Adaptive’s immunoSEQ, an immune profiling assay that identifies T and B cell receptors. HS-410 is in Phase...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Financial News

Heat Biologics completes warrant exercise

Heat Biologics Inc. (NASDAQ:HTBX), Durham, N.C.   Business: Cancer, Infectious   Date completed: 2016-09-30   Type: Warrant exercise   Raised: $2.8 million   Shares outstanding prior: 19.5 million   Investor: Existing investors   Note: Heat...